CPTCF (Cytophage Technologies) Accumulated Depreciation: $-1.59 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CPTCF Cytophage Technologies Ltd CPTCF
18 GF Score
Price $0.21
! 1 Warning Sign
View Full Analysis

What is Cytophage Technologies Accumulated Depreciation?

Cytophage Technologies CPTCF 18 Accumulated Depreciation is $-1.59 Mil as of Dec. 2025. GuruFocus rates CPTCF with a GF Score™ of 18/100. The stock has 1 warning sign investors should review.

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Cytophage Technologies's quarterly accumulated depreciation increased from Jun. 2025 ($-1.42 Mil) to Sep. 2025 ($-1.47 Mil) and increased from Sep. 2025 ($-1.47 Mil) to Dec. 2025 ($-1.59 Mil).

Cytophage Technologies's annual accumulated depreciation declined from Dec. 2023 ($-1.13 Mil) to Dec. 2024 ($-1.06 Mil) but then increased from Dec. 2024 ($-1.06 Mil) to Dec. 2025 ($-1.59 Mil).

Cytophage Technologies Accumulated Depreciation Related Terms

Cytophage Technologies Accumulated Depreciation Historical Data

* Premium members only.

The historical data trend for Cytophage Technologies's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cytophage Technologies Accumulated Depreciation Chart

Cytophage Technologies Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Accumulated Depreciation
-0.49 -0.73 -1.13 -1.06 -1.59

Cytophage Technologies Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Accumulated Depreciation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.06 -1.23 -1.42 -1.47 -1.59
CPTCF
18GF Score
Cytophage Technologies Ltd CPTCF
Accumulated Depreciation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cytophage Technologies Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

What does a Accumulated Depreciation of $-1.59 Mil mean?
Cytophage Technologies (CPTCF) has a Accumulated Depreciation of $-1.59 Mil as of Dec. 2025. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Cytophage Technologies and its competitors.
Is Cytophage Technologies' Accumulated Depreciation too high?
Cytophage Technologies' current Accumulated Depreciation is $-1.59 Mil. Overall, Cytophage Technologies has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Cytophage Technologies' Accumulated Depreciation compare to VRTX and REGN?
Cytophage Technologies' Accumulated Depreciation of $-1.59 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accumulated Depreciation for a Biotechnology company?
A good Accumulated Depreciation depends on the Biotechnology industry context. However, Accumulated Depreciation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accumulated Depreciation mean?
A high Accumulated Depreciation can signal that a stock is expensive relative to its fundamentals. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Cytophage Technologies and its competitors. Cytophage Technologies's current Accumulated Depreciation is $-1.59 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cytophage Technologies stock overvalued right now?
Cytophage Technologies (CPTCF) has a current Accumulated Depreciation of $-1.59 Mil. The current Accumulated Depreciation is $-1.59 Mil. Cytophage Technologies' overall GF Score™ is 18/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accumulated Depreciation calculated?
Accumulated Depreciation is calculated from a company's financial statements. For Cytophage Technologies (CPTCF), the current Accumulated Depreciation is $-1.59 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cytophage Technologies Business Description

Other Exchanges CYTO.H:Canada
Address 400 Fort Whyte Way, Suite 200A, Oak Bluff, MB, CAN, R4G 0B1
Cytophage Technologies Ltd is a Canadian biotechnology company engaged in the development of bacteriophages using molecular genetics and synthetic biology techniques. The company focuses on developing bacteriophage-based solutions to address bacterial challenges affecting animal health, human health, and food security, including antibiotic-resistant bacterial strains.
18GF Score

Get the complete analysis for CPTCF

Accumulated Depreciation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.21
Price